Bright Minds Biosciences Inc. announced compelling preclinical results for its investigational compound BMB-201, in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. BMB-201 produced statistically significant reductions in facial mechanical allodynia across both male and female cohorts at 1 and 2 hours post-dose, compared to vehicle, and demonstrated greater effect sizes than sumatriptan at multiple timepoints. Key Results: Robust efficacy versus vehicle at 1 and 2 hours in both sexes (periorbital von Frey thresholds).
Benchmark comparison: BMB-201 showed greater effect sizes than sumat SAPan at multiple timepoints and doses (e.g., males: BMB-201 86% vs. sumatriptan 81% at 1h; 53-64% vs. 44% at 2h; females: BMB-201 76-100% at 1h vs.
1h vs. sumatriptan 56%; 80% at 2h vs. 63%).
